Summary of findings 5. Budesonide 9 mg versus prednisolone 40 mg for maintenance of remission in Crohn's disease.
| Budesonide 9 mg versus prednisolone 40 mg for maintenance of remission in Crohn's disease | ||||||
| Patient or population: patients with quiescent Crohn's disease Settings: outpatients Intervention: budesonide 9 mg versus prednisolone 40 mg | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | Budesonide 9 mg versus prednisolone 40 mg | |||||
| Continued remission at 12 months | 636 per 10001 | 502 per 1000 (350 to 719) | RR 0.79 (0.55 to 1.13) | 90 (1 study) | ⊕⊕⊝⊝ Low2,3 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: risk ratio | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Control group risk estimates come from control arm of meta‐analysis, based on included trials. 2 Sparse data (51 events). 3 High risk of bias due to lack of blinding.